Checkpoint | Foveal Research 3/3

ADC: AZN Dato overall survival misses underscores our long held concerns for ADC's in 1L Lung

WCLC: Hold you HARMONis: Keytruda safe from Summit

ADCs @ ASCO: concerns over Dato-DXd in 1L Lung; GILD 2L OS as bad as AZN; SKB high ORR in unusual trial

MRNA/MRK: ASCO cancer vaccine data does not address pre-treatment imbalances that may be driving result

ROG/SRPT: Duchenne EMBARK likely enought to lessen age restrictions

AZN/ROG: Roche/AZN: SERDs restrict or fail

May 27, 2015

ASCO Late Breakers to watch

ASCO PD1 Late breakers in Lung, Melanoma, Colon, Liver and Head & Neck With ASCO abstracts already out, the currently embargoed late...

May 19, 2015

ROG.VX: Roche's anti PD-L1 must be restricted in 2nd line lung unlike competitor, without superi

Roche's MPDL worse than chemo in 2nd line PD-L1-ve lung, but doesn't have better data in PDL1 +ves either Much excitement has been caused...

Mar 31, 2015

Honing in on targeted therapy may take the sting out of the PD-1 market

Anti PD-1 commercial potential may be vastly overestimated With PD-1 checkpoint inhibition clearly set to improve the landscape of cancer...

ADC: AZN Dato overall survival misses underscores our long held concerns for ADC's in 1L Lung

Oct 3

WCLC: Hold you HARMONis: Keytruda safe from Summit

Sep 22

ADCs @ ASCO: concerns over Dato-DXd in 1L Lung; GILD 2L OS as bad as AZN; SKB high ORR in unusual trial

Jul 1

MRNA/MRK: ASCO cancer vaccine data does not address pre-treatment imbalances that may be driving result

Jun 18

ROG/SRPT: Duchenne EMBARK likely enought to lessen age restrictions

May 29

AZN/ROG: Roche/AZN: SERDs restrict or fail

Apr 23

CYTK/BMY: aficamten approvable, but may not be better than BMY rival Camzyos

Feb 29

MRK: One big hit amongst smaller approvable assets

Feb 5

BMY/JNJ/BAYN: Bayer AF failure does not reduce chances for Factor XI in stroke

Nov 20, 2023

Foveal LLP Independent Investment Research Foveal Research